SQUAMOUS NON-SMALL-CELL LUNG CANCER
Clinical trials for SQUAMOUS NON-SMALL-CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS NON-SMALL-CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for SQUAMOUS NON-SMALL-CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug ALE.P02 targets Tough-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called ALE.P02 in people with advanced or spreading squamous cell cancers of the lung, head and neck, cervix, or esophagus. The drug is designed to find and attack cancer cells that have a specific protein (Claudin-1). The main goals are to check the d…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated May 26, 2026 03:04 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, ALE.P03, that delivers a cancer-killing agent directly to tumor cells with a specific marker (CLDN1). It is for adults with advanced or metastatic cancers of the cervix, lung, colon, bile duct, or bladder that have not responded to standard treatments…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental pill, VLS-1488, in people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a protein that helps cancer cells divide. The trial has two parts: first finding a safe dose, then checking if it shrinks …
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Volastra Therapeutics, Inc. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New drug AZD8205 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called AZD8205, alone or with other cancer drugs, for people with advanced solid tumors like breast, ovarian, or lung cancer that have stopped responding to standard treatments. The main goals are to check safety and find the right dose. About 460 adul…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
Personalized vaccine plus immunotherapy shows promise against tough lung cancer
Disease control Recruiting nowThis study tests whether adding a personalized cancer vaccine (V940) to standard immunotherapy (pembrolizumab) and chemotherapy helps people with advanced squamous non-small cell lung cancer live longer and keep their cancer from growing. About 180 participants will receive eithe…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 18, 2026 12:11 UTC